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Prostaglandin (PG)-related ophthalmic solutions, which only recently became available for clinical use, are currently the most 
widely used solutions in the treatment of glaucoma, because they have excellent ocular hypotensive effects with little adverse 
effects. With respect to the pharmacological mechanism of action of these solutions, the mechanism of intraocular pressure (IOP) 
reduction for latanoprost, the first drug in this class to become available, is to promote the outflow of aqueous humor through 
the uveoscleral route, an important aqueous humor outflow tract. Molecular and cellular studies have shown that latanoprost 
affects the extracellular matrix metabolism in the uveoscleral route. For other PG-related ophthalmic solutions, there is no 
consensus opinion on their effects on the aqueous humor outflow tract, and how they reduce the IOP remains largely unclear. 
The docosanoid, isopropyl unoprostone, has excellent ocular hypotensive effects, despite having extremely low affinities to the 
known PG receptors. Many basic and clinical studies have demonstrated that PG-related ophthalmic solutions themselves cause 
not only a decrease in the IOP, but also induce endogenous PGs which could lead to secondary effects that may account in part 
for the IOP reduction. PG-related ophthalmic solutions have essentially no clinically important systemic adverse effects, but often 
have local adverse effects. The most characteristic is the pigment deposition in the iris or eyelid. Corneal epitheliopathy is also 
relatively common. In addition, as an adverse effect that affects vision, cystoid macular edema can be seen. Current studies are 
aimed at elucidating the mechanisms of development of these adverse effects, and thus to establish measures to prevent them. We 
compare the mechanisms of action of PG-related ophthalmic solutions and review the adverse effects and their mechanisms.  
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HISTORY OF DEVELOPMENT OF PROSTAGLANDIN-RELATED 
OPHTHALMIC SOLUTIONS
In 1981, Camras and Bito (1) demonstrated that ophthalmic ad-
ministration of prostaglandin (PG)F2α caused a decrease in the 
intraocular pressure (IOP). However, because PGF2α caused 
initially an increase in the IOP and also induced severe local 
irritation, further studies were conducted to overcome these 
side effects. These studies led to the development and eventual 
clinical use of the PGF2α-related agent, latanoprost, as the first 
anti-glaucoma solution in this class. Later, studies by Goh et 
al (2) in Japan led to the development of the docosanoid, iso-
propyl unoprostone (referred to unoprostone thereafter), which 
was approved for clinical use in Japan in 1994. Thereafter, the 
prostanoid, bimatoprost, became available in 1997 and another 
PGF2α-related agent, travoprost, became available in 1999. 
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Currently, the above four PG-related ophthalmic solutions are 
in clinical use in the US. The structures of these compounds 
are shown in Figure 1.
STRUCTURAL FEATURES AND COMPARISON 
OF PG-RELATED OPHTHALMIC SOLUTIONS
The IOP is determined by the production and outflow of the 
aqueous humor, and as indicated in Figure 2, humans have 
two aqueous humor outflow routes. The aqueous humor is 
produced by the ciliary body epithelial cells, passes through the 
pupillary region and flows towards the iridocorneal angle. The 
outflow tract from the iridocorneal angle through the trabecular 
meshwork and the canal of Schlemm to the venous circulation 
is called the conventional outflow route, and this is the major 
aqueous humor outflow tract occupying more than 90% of 
total outflow in normal eye. The system from the iridocorneal 
angle between the ciliary muscle bundles and the subscleral 
space is called the uveoscleral outflow route. In normal eyes, 
it accounts for less than 10% of the total aqueous humor 
outflow. The aqueous humor outflow from the conventional 
route changes depending on the IOP, but the efficiency of the 
uveoscleral outflow is unaffected by the IOP.  
   The widely used conventional glaucoma treatment drugs, 
Figure 1. Structures of 
PG-related ophthalmic
solutions.
Figure 2. Scheme of major 
aqueous outflow routes.
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beta-blockers and carbonic anhydrase inhibitors, inhibit 
the production of the aqueous humor from the ciliary body 
epithelial cells and decrease the IOP. Pilocarpine increases 
the conventional outflow and decreases the IOP.  The major 
mechanism of IOP reduction by the PG-related ophthalmic 
solutions is thought to be the promotion of the uveoscleral 
outflow, but some PG-related ophthalmic solutions have also 
been suggested to increase the conventional outflow, although 
the details are unknown. This review will mainly summarize 
the pharmacological mechanism of action of latanoprost in 
reducing the IOP, since much progress has been made in the 
research of this drug. Although the PG-related anti-glaucoma 
ophthalmic solutions have only few systemic adverse effects, 
they are known to cause local adverse effects, such as in-
creased pigmentation of the iris, hypertrichosis of the eyelids, 
and cystoid macular edema. This review also summarizes the 
mechanisms underlying these adverse effects.  
MECHANISM OF IOP REDUCTION BY LATANOPROST 
Latanoprost was developed on the basis of studies by J. Stjern-
schantz and L. Bito, and its clinical use began in North America 
and Europe in 1995 (3). Its structure is similar to PGF2α (Fig. 1) 
and has a high PGF2α (FP) receptor selectivity. Of the aqueous 
humor outflow routes indicated in Figure 2, latanoprost has no 
effect on the conventional outflow but promotes the uveoscleral 
outflow of the aqueous humor, thereby decreasing the IOP. The 
promotion of the uveoscleral outflow of the aqueous humor 
has been attributed to (i) ciliary muscle relaxation, resulting 
in greater gaps between the muscle bundles, thus allowing 
greater outflow of the aqueous humor, and (ii) remodeling of 
the extracellular matrix (ECM) surrounding the ciliary muscle 
bundles, thus promoting the outflow of the aqueous humor 
through the ECM. However, a number of reports contradict 
the former theory. Namely, although pilocarpine can increase 
muscle contraction and decrease the uveoscleral outflow, it 
does not interfere with the IOP lowering effects when used 
concurrently with latanoprost, but rather has synergistic ef-
fects to decrease the IOP. Further, the latanoprost-mediated 
relaxation of the ciliary muscle (which has an important role in 
accommodation) could affect refraction, but no such changes 
were observed clinically (4-7) after latanoprost application. 
Thus, ciliary muscle relaxation effect, if present, would be mild 
and only a part of the mechanism of IOP reduction.  
   We now focus on the studies investigating the remodeling 
of the ciliary body ECM. Tamm et al (8) studied the changes 
in the ciliary muscle structure caused by PGF2α in humans and 
found that the smooth muscle cells lose their connection to the 
extracellular fibrils because of PGF2α-induced lysis of extra-
cellular material. That raised the possibility that PGs might 
affect the ECM (8). The Weinreb group conducted in vitro 
experiments and reported that the PGF2α acts on the ciliary 
muscle cells at the AP-1 site and increases the expression of 
c-FOS (9), and that latanoprost increases the expression of the 
mRNA (10) and protein (11) of the ECM degrading enzyme, 
matrix metalloproteinase (MMP), induces an increase in the 
MMP release by ciliary smooth muscle cells (12), and affects 
the content of collagen, a major ECM component (13). Similar 
data was reported by Ocklind, both in vitro and in vivo (14). 
Figure 3 shows zymography indicating the changes in the 
MMP activity when cultured ciliary muscle cells are treated 
with PG-related solutions. These data strongly suggest that 
latanoprost affects the ECM remodeling in the ciliary body 
as summarized in Table 1. However, these changes occurred 
Figure 3. Effects of PG-related agents 
on matrix metalloproteinase activity.
Substrate zymography shows that 
PG-related agents (200 mM each) 
increase MMP activities with 48 hour-
exposure. Bands at 97 kD, 98 kD, and 
63 kD correspond to MMP-9, MMP-2, 
and MMP-1 activity, respectively.
17PT-PGF2α=17 phenyl-trinor-
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Table 1. Effects of topical latanoprost on ECM and MMPs in monkey eyes
in the ECM long time after latanoprost treatment and thus 
cannot explain the significant decrease in the IOP seen clini-
cally 2-3 hour after ophthalmic administration. At present, it 
may be suggested that both the ciliary muscle relaxation and 
the ECM changes contribute to the promotion of the aqueous 
humor outflow.  
MECHANISM OF IOP REDUCTION BY UNOPROSTONE
Unoprostone is 13,14-dihydro-15-keto-20-ethyl-PGF2α-
isopropyl ester developed in Japan. It became available for 
clinical use in 1994 in Japan, and in 2001 in North America. As 
indicated in Figure 1, it has a ketone group at position 15 and 
has very low selectivity toward any of the known PG-receptors 
(15). Furthermore, unoprostone is rapidly metabolized in the 
eye after ophthalmic administration (16). Figure 4 shows the 
intraocular metabolism of latanoprost and unoprostone. The 
major pharmacologically active component in the eye is not 
unoprostone but rather is likely to be its metabolite(s)(Fig. 5). 
However, the metabolites have PG receptor affinities that are 
even lower than unoprostone itself (personal communication). 
Therefore, it seems unlikely that the mechanism of action of 
this drug is through pharmacological effects on the previously 
reported PG receptors.
   The mechanism of IOP reduction by unoprostone has been 
proposed to be either promotion of aqueous humor through 
the conventional route (17) or an increase in the uveoscleral 
outflow, but there is no agreement regarding this issue. As 
with latanoprost, unoprostone has been reported to increase 
the MMP activity in in vitro experiments (Fig. 6)(18), but it 
remains unclear why the PG receptor affinity is extremely low 
even though the drug has pharmacological activity. As seen 
for latanoprost (19), the intraocular unoprostone metabolite(s) 
can induce endogenous PGF2α and PGE2 (Fig. 7)(20), and 
the induction of endogenous PGs may contribute to the drug 
activity. However, the details of the mechanisms of IOP re-
duction by unoprostone remain unclear.  
MECHANISM OF IOP REDUCTION BY BIMATOPROST
Bimatoprost, which is (Z)-7-[(1R, 2R, 3R, 5S)-3, 5-dihydroxy-
2-[(1E, 3S)-3-hydroxy-5-phenyl-1-pentenyl] cyclopentyl]-5-
N-ethyl heptenamide, has a chemical structure (Fig. 1) simi-
lar to the PGF2α analogues. The free acid of bimatoprost is 
identical to that of latanoprost with the exception of a double 
bond instead of single bond at the carbon 13-14 position. A 
recent study has demonstrated binding of bimatoprost to the 
FP prostanoid receptor. The free acid of bimatoprost is known 
to be a potent FP receptor agonist.
   Bimatoprost enhances the pressure-sensitive outflow path-
way. There is a report of additional beneficial effects that may 
include an increase in the rate of flow in the uveoscleral outflow 
pathway and lowering of the episcleral venous pressure (21), 
but the detailed mechanisms are unknown.  
MECHANISM OF IOP REDUCTION BY TRAVOPROST 
Travoprost (AL-6221), which is isopropyl (Z)-7-[(1R, 2R, 
3R, 5S)-3, 5-dihydroxy- 2-[(1E, 3R)-3-hydroxy-4-[(α, α, α-
trifluoro-m-tolyl)oxy]-1-butenyl]cyclopentyl]-5-heptenoate, 
is the isopropyl ester of a single enantiomer of the selective 
FP prostaglandin receptor agonist, fluprostenol. It is a PG 
analogue with a high FP receptor selectivity (22) and pro-
motes aqueous humor outflow via the uveoscleral route (23). 
Its ability to decrease the IOP seem to be better than timolol 
and equivalent to latanoprost. Only a few adverse effects are 
known. However, a detailed mechanism of reduction in the 
IOP has not been elucidated.  
Protein Ciliary Muscle Iris Root Sclera adjacent to 
   the ciliary body 
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Figure 4. Intraocular metabolism of latanoprost and unoprostone.
Figure 5. Concentrations of unoprostone ant its metabolites (M1 and M2) in the anterior chamber.
Note that no unoprostone but only M1 and M2 are detected in the anterior chamber when a single drop of radioisotope-labeled 
unoprostone was administered to rabbit eyes. Bar, standard deviation, n = 4. Modified from reference 16.
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(b) Changes of MMP-2 activity in a medium from ciliary muscle cells. Y axis represents % of MMP-2 activity over the 
vehicle control, * p < 0.05, † p = 0.06, versus control; bar, standard deviation, n = 5. Modified from reference 18.
Figure 6. Effects of unoprostone metabolites on matrix metalloproteinase acitivity.
(a) A representative result 
of substrate zymo-
graphy. M1 and M2 
increase MMP-2 and 
9 activities compared 
with vehicle control. 
 Lanes:
 1. Vehicle
 2. 10 nM M1
 3. 10 nM M2
 4. 10 µM M1
 5. 10 µM M2
†
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ADVERSE EFFECTS CAUSED BY PG-RELATED AGENTS 
Increased pigmentation of the iris 
A frequently seen adverse effect of the currently available 
PG-related solutions is the increased pigmentation of the iris 
(24-27). Figure 8 shows representative iridial pigmentation 
induced by either latanoprost or unoprostone. The mechanism 
of pigment deposition by latanoprost involves increase of the 
tyrosinase activity without inducing cell division in the iris 
or dermal melanocytes, and thus causing melanin increase 
(Fig. 9)(27-34). Our results showed that in addition to the 
increased melanogenesis by increased tyrosinase activity, 
latanoprost but also causes an increased pigmentation of mela-
nin (28,29). We and others reported an increase in eumelanin/
pheomelanin ratio in the latanoprost-administered animal 
models (28,29,35). We have observed the same effect also 
for unoprostone, but with a lower incidence of the increased 
pigmentation compared to latanoprost (28). Other PG-related 
agents have also been reported to increase the pigmentation of 
the iris, but the details remain unclear. The increased melanin is 
not released outside of the cell, and there is no increase in the 
melanin deposition in the iridocorneal angle and other ocular 
tissues. IOP elevation or a malignant transformation have not 
been observed. Thus, at this point, this complication remains 
only an esthetic problem.   
Hair-growth 
Recently, latanoprost has been recognized as a drug capable of 
regularly inducing hypertrichosis involving eyelashes, adjacent 
adnexal hair, and vellus hair of the skin (36,37). Hair growth 
cycle involves the anagen, catagen, and telogen, and latano-
prost has been suggested to cause longer anagen follicle phase 
than normal compared to the telogen follicle phase (38). This 
effect is said to be reversible, but this has not been confirmed. 
Hair growth involves many genes and growth factors that af-
fect the hair growth and hair cycling, and how latanoprost is 
implicated remains unclear.
Recurrence of uveitis 
There have been reports of uveitis recurring in patients with a 
history of uveitis treated with latanoprost. The mechanism is 
not well understood. Latanoprost has been reported to induce 
PGE2, an PG involved in inflammation (20), which may be 
involved in this phenomenon.  
Cystoid macular edema (CME)  
CME is an important local adverse effect seen in PG-related 
solutions because it affects vision. CME is thought to be more 
frequent in patients with a history of intraocular surgery, where 
the blood/aqueous humor barrier has been affected. Figure 
10 shows a representative case with cystoid macular edema 
induced by latanoprost ophthalmic solution. The details of 
the pathogenetic mechanism is unclear, but the involvement 
of endogenous PGE2 has been proposed, because latanoprost 
induces endogenous PGE2 (20), and because concurrent ad-
ministration of non-steroidal anti-inflammatory drugs with 
Figure 7. Effects of latanoprost and unoprostone on the release of endogenous PGE2 from isolated iris tissue.
All examined compounds increased the release of endogenous PGE2 compared with the control. 1 µM M2, latanoprost, and 
PGF2α significantly induce the release of PGE2 by isolated iris tissue. Each experiment was performed in duplicate (n= 4). 
* p = 0.02, † p = 0.03, § p < 0.05 versus control, ANOVA followed by post-hoc. LA, acid of latanoprost; bar, SEM.
† § 
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Figure 8. Representa-
tive cases of PG-induced 
iridial pigmentation. Before 
treatment of PG-related 
ophthalmic solution, iridial 
pigmentation was normal (a, 
c). After initiation of PG-re-
lated ophthalmic solution, 
scattered pigmentation was 
observed and iridial pig-
mentation was gradually 
increased (b, latanoprost; 
d, unoprostone). The pattern 
of increased pigmentation by 
unoprostone was similar to 
that by latanoprost.
c d
Figure 9.  A schematic 
diagram of melanogenic 
pathway. PG-related oph-
thalmic solutions could 
increase tyrosinase activity 
and influence the nature of 
melanin converting normal 






dole-2-carboxylic acid.  
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latanoprost after cataract surgery suppresses the develop-
ment of CME (39). This adverse effect is rare in patients with 
no history of breakdown of the blood/aqueous humor barrier 
(40), and it is therefore considered that the administration of 
latanoprost should be performed with caution in patients with 
a history of barrier breakdown. CME has not been reported 
with unoprostone, probably because of the rapid intraocular 
metabolism of unoprostone and its conversion into inactive 
compound(s)(16). There are no data concerning the develop-
ment of this adverse effect in the other two PG-related solutions 
because of the short time elapsed after their approval.  
CONCLUSION
The pharmacological action of the PG-related agents is pre-
dominantly to promote the uveoscleral outflow of aqueous 
humor. Their introduction has increased the interest in the 
uveoscleral outflow, which previously had not received 
much attention. At the same time, many questions remain 
unanswered. It is widely recognized that uveoscleral outflow 
in the physiological state accounts for only 10% of the aqueous 
humor outflow, and it remains unclear how the PG-related 
solutions can then cause a remarkable IOP decrease. The 
conventional route is directly in contact with the veins and thus 
is affected by the venous pressure, while the uveoscleral route 
is not directly connected to the vasculature and is not affected 
by the venous pressure. Thus, the uveoscleral route may reduce 
the IOP more effectively than the conventional route, because 
its use is not limited by the effects of the venous pressure. 
Therefore, the approach involving the uveoscleral outflow has 
attracted new attention in the treatment of glaucoma. 
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